Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential...
Related Questions
How will the $42.5 million upfront payment and potential milestone payments affect Jazz Pharmaceuticals' cash flow and earnings guidance?
What are the expected timelines for SAN2355's development milestones and potential regulatory approvals, and how might those dates influence the stock's valuation?
How does this exclusive licensing deal compare to Jazz's previous collaborations in terms of upside potential and risk exposure, and what could it mean for the company's long‑term growth trajectory?